New pill could help patients with rare blood disorder
NCT ID NCT05002777
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called rilzabrutinib in 22 adults with warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. Participants take the drug daily for up to 24 weeks, with an option to continue longer. The main goal is to see if it raises hemoglobin levels and reduces the need for blood transfusions or rescue medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rilzabrutinib (a drug taken as a tablet by mouth)
What this could lead to
If it works, this could offer a new oral treatment option for people with warm autoimmune hemolytic anemia who have not responded well to steroids.
What could go wrong
This is a small, early-phase (Phase 2) study with only 22 participants, so results may not apply to everyone. The drug may not work as hoped or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts Health NHS Trust_Investigational Site Number: 8260005
London, E1 2ES, United Kingdom
-
Fejer Varmegyei Szent Gyorgy Egyetemi Oktato Korhaz_Investigational Site Number: 3480001
Székesfehérvár, 8000, Hungary
-
Georgetown University Hospital_Investigational Site Number: 8400003
Washington D.C., District of Columbia, 20007, United States
-
Hanush-Krankenhaus_Investigational Site Number: 0400001
Vienna, 1140, Austria
-
Hospital Clinic de Barcelona_Investigational Site Number: 7240001
Barcelona, 08036, Spain
-
Hospital Universitario La Paz_Investigational Site Number: 7240003
Madrid, 28046, Spain
-
Hospital Universitario Virgen del Rocío_Investigational Site Number: 7240002
Seville, 41013, Spain
-
Hospital Universitario de Cruces_Investigational Site Number: 7240004
Barakaldo, 48093, Spain
-
Imperial College Healthcare NHS Trust_Investigational Site Number: 8260002
London, W2 1NY, United Kingdom
-
Institute of hematology&blood diseases hospital_Investigational Site Number: 1560003
Tianjin, 300020, China
-
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"_Investigational Site Number: 3800003
Meldola, 47014, Italy
-
Klinik für Hämatologie und Stammzellentransplantation_Investigational Site Number: 2760001
Essen, 45147, Germany
-
Leeds Teaching Hospitals NHS Trust_Investigational Site Number: 8260001
Leeds, LS9 7TF, United Kingdom
-
Massachusetts General Hospital_Investigational Site Number: 8400001
Boston, Massachusetts, 02114, United States
-
Odense Universitetshospital Hæmatologisk Forskningsenhed_Investigational Site Number: 2080001
Odense, 5000, Denmark
-
Oncology & Hematology Associates of West Broward_Investigational Site Number: 8400002
Tamarac, Florida, 33321, United States
-
Ospedale Giuseppe Moscati_Investigational Site Number: 3800002
Avellino, 83100, Italy
-
Ospedale Maggiore Policlinico_Investigational Site Number: 3800001
Milan, 20149, Italy
-
Peking Union Medical College Hospital_Investigational Site Number: 1560002
Beijing, 100005, China
-
TOI Clinical Research LLC_ Cerritos_Investigational Site Number: 8400006
Cerritos, California, 90703, United States
-
TOI Clinical Research LLC_ Whittier_Investigational Site Number: 8400006
Whittier, California, 90602, United States
-
TOI Clinical Research LLC_Glendale_Investigational Site Number: 8400006
Glendale, California, 91204, United States
-
TOI Clinical Research LLC_Long Beach_Investigational Site Number: 8400006
Long Beach, California, 90805, United States
-
TOI Clinical Research LLC_Santa Ana_Investigational Site Number: 8400006
Santa Ana, California, 92705, United States
-
The Lundquist Institute_Investigational Site Number: 8400005
Torrance, California, 90502, United States
-
The Oncology Institute of Hope & Innovation Site Number : 8400006
Cerritos, California, 90703, United States
-
University of Southern California_Investigational Site Number: 8400009
Los Angeles, California, 90033, United States